News & Updates

Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.

In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.

Children with juvenile idiopathic arthritis (JIA) show similar well-being and academic performance as those without JIA, according to a study.

Tofacitinib demonstrates greater efficacy than placebo at week 12 in patients with ankylosing spondylitis (AS) regardless of their baseline C-reactive protein (CRP) levels, a study has shown.